{
    "hands_on_practices": [
        {
            "introduction": "Effective management of dermatitis herpetiformis often begins with a complex conversation, particularly when a patient is unable or unwilling to adopt the cornerstone gluten-free diet. This practice places you in this common clinical dilemma, challenging you to develop a comprehensive and ethical management plan. This exercise  hones your skills in shared decision-making, balancing the need for rapid symptomatic relief with the crucial responsibility of communicating long-term risks and coordinating systemic surveillance.",
            "id": "4433722",
            "problem": "A patient aged $34$ years presents with intensely pruritic grouped vesicles and excoriated papules on the extensor surfaces. Histopathology of a lesional biopsy demonstrates neutrophilic microabscesses in dermal papillae, and direct immunofluorescence reveals granular immunoglobulin A (IgA) deposition at the dermal papillary tips consistent with dermatitis herpetiformis. Serum immunology shows elevated anti–tissue transglutaminase IgA consistent with small intestinal gluten-driven autoimmunity. After discussing that strict gluten elimination is the cornerstone of disease control, the patient states they are unwilling to adopt a gluten-free diet due to socioeconomic constraints but would like symptomatic relief. \n\nUsing first principles of autoimmunity and immune-mediated tissue injury, select the management plan that most appropriately balances: \n- risk communication about persistent autoimmunity and enteropathy-associated T-cell lymphoma risk with ongoing gluten exposure, \n- the limitations of pharmacologic suppression on disease biology, and \n- a realistic, ethically sound care pathway centered on shared decision-making, safety monitoring, and mitigation of extra-cutaneous complications.\n\nAll acronyms must be understood as follows on first use: glucose-6-phosphate dehydrogenase (G6PD), complete blood count (CBC), liver function tests (LFTs), direct immunofluorescence (DIF), enteropathy-associated T-cell lymphoma (EATL).\n\nChoose the single best option.\n\nA. Reassure the patient that lymphoma risk is negligible in dermatitis herpetiformis, start dapsone without baseline testing, schedule follow-up as needed, and forgo gastroenterology involvement since cutaneous control suffices.\n\nB. Engage in shared decision-making to convey that ongoing gluten exposure perpetuates autoantigen stimulation and thus maintains mucosal autoimmunity and increases lymphoma risk relative to strict gluten avoidance; initiate dapsone for rapid cutaneous symptom control at the lowest effective dose with baseline G6PD screening, CBC, LFTs, and methemoglobin assessment plus periodic monitoring; counsel on adverse effects (hemolysis, methemoglobinemia, agranulocytosis, neuropathy) and consider sulfapyridine or sulfasalazine if dapsone is contraindicated; coordinate gastroenterology follow-up to monitor celiac serologies, nutritional status (iron, folate, vitamin D), and bone mineral density, with endoscopic evaluation only if clinically indicated; discuss vaccinations pertinent to potential hyposplenism; explicitly state that pharmacologic suppression does not reduce intestinal autoimmunity or malignancy risk, and set a plan to revisit dietary adoption when feasible.\n\nC. Start long-term systemic corticosteroids to suppress skin inflammation and allow normal diet, emphasizing that steroid immunosuppression will offset lymphoma risk, and defer laboratory monitoring to reduce burden.\n\nD. Initiate an anti–tumor necrosis factor biologic for cutaneous control, discontinue discussion of gluten-free diet, and rely on the biologic to prevent enteropathy-associated complications, with no need for G6PD, CBC, or LFT assessment.\n\nE. Insist on strict gluten elimination as the sole therapy and withhold pharmacologic agents, accepting persistent pruritus until the patient changes their mind about diet, since symptom control is secondary to immunologic cure.",
            "solution": "### Step 1: Extract Givens\n- **Patient Age:** $34$ years\n- **Clinical Presentation:** Intensely pruritic grouped vesicles and excoriated papules on the extensor surfaces.\n- **Histopathology:** Neutrophilic microabscesses in dermal papillae.\n- **Direct Immunofluorescence (DIF):** Granular immunoglobulin A (IgA) deposition at the dermal papillary tips.\n- **Diagnosis:** Dermatitis herpetiformis.\n- **Serum Immunology:** Elevated anti–tissue transglutaminase (anti-tTG) IgA.\n- **Underlying Pathophysiology:** Small intestinal gluten-driven autoimmunity (celiac disease).\n- **Patient Preference/Constraint:** Unwilling to adopt a gluten-free diet due to socioeconomic constraints.\n- **Patient Goal:** Symptomatic relief.\n- **Task Objective:** Select the management plan that appropriately balances risk communication (persistent autoimmunity, enteropathy-associated T-cell lymphoma (EATL) risk), limitations of pharmacology, and a realistic, ethically sound pathway (shared decision-making, safety monitoring, mitigation of extra-cutaneous complications).\n- **Acronym Definitions:** glucose-6-phosphate dehydrogenase (G6PD), complete blood count (CBC), liver function tests (LFTs), enteropathy-associated T-cell lymphoma (EATL).\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is scientifically and medically sound. The described clinical, histopathological, and immunofluorescence findings are the classic triad for diagnosing dermatitis herpetiformis. The link between dermatitis herpetiformis and gluten-sensitive enteropathy (celiac disease) is a fundamental, well-established principle in dermatology and gastroenterology. The patient's situation, where socioeconomic factors are a barrier to adopting a strict gluten-free diet, is a realistic and common clinical challenge. The task is well-posed, asking for the optimal management strategy by balancing efficacy, safety, patient autonomy, and long-term risk management based on established principles of pathophysiology, pharmacology, and medical ethics. The problem is objective, free of contradictions, and contains sufficient information to be addressed through clinical reasoning.\n\n### Step 3: Verdict and Action\nThe problem is valid. The solution will proceed by deriving the appropriate management plan from first principles and then evaluating each option.\n\n### Derivation from First Principles\n1.  **Pathophysiology:** Dermatitis herpetiformis (DH) is the specific cutaneous manifestation of celiac disease. Ingestion of gluten by genetically susceptible individuals triggers an autoimmune response. This leads to the production of IgA autoantibodies against tissue transglutaminase (tTG), an enzyme found in the gut (tTG₂), and epidermal transglutaminase (tTG₃), an autoantigen in the skin. The deposition of these IgA autoantibodies at the tips of the dermal papillae activates the complement cascade and recruits neutrophils, causing the characteristic inflammation, microabscess formation, and intensely pruritic vesicles.\n\n2.  **Therapeutic Goals:** The management of DH has two distinct goals:\n    *   **Control of Underlying Autoimmunity:** This is achieved by complete and lifelong elimination of the antigenic trigger, which is gluten. A strict gluten-free diet (GFD) is the only intervention that addresses the root cause of the disease. It leads to the resolution of the intestinal enteropathy, a gradual decline in autoantibody titers, eventual clearance of skin lesions (over months to years), and, most importantly, reduces the long-term risk of celiac disease-associated complications, including nutritional deficiencies, osteoporosis, and malignancies like enteropathy-associated T-cell lymphoma (EATL).\n    *   **Symptomatic Control of Skin Disease:** For rapid relief of pruritus and skin lesions, especially while a GFD is taking effect or if a GFD is not followed, pharmacologic therapy is required.\n\n3.  **Pharmacology and Safety:** The first-line drug for symptomatic control of DH is dapsone. Dapsone is a sulfone antibiotic with potent anti-inflammatory effects, primarily through the inhibition of neutrophil migration and function. It offers rapid relief, often within $24$-$48$ hours. However, dapsone has a significant risk profile requiring strict safety monitoring:\n    *   **Hemolytic Anemia:** Dapsone induces a dose-dependent oxidative stress on red blood cells, leading to hemolysis in all patients. This effect is drastically exacerbated and can be life-threatening in individuals with a deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is essential for protecting red blood cells from oxidative damage. **Therefore, screening for G6PD deficiency is mandatory before initiating dapsone.**\n    *   **Methemoglobinemia:** Dapsone oxidizes hemoglobin to methemoglobin, which cannot bind oxygen. This is also dose-dependent. Baseline and follow-up monitoring of methemoglobin levels are necessary.\n    *   **Agranulocytosis:** A rare ($~1$ in $10,000$) but potentially fatal idiosyncratic reaction (severe neutropenia) that typically occurs within the first $3$ months of therapy. Regular monitoring of the complete blood count (CBC) is essential.\n    *   **Hepatotoxicity and Neuropathy:** Less common adverse effects that warrant monitoring of liver function tests (LFTs) and clinical assessment for neuropathy.\n    If dapsone is contraindicated (e.g., G6PD deficiency) or not tolerated, alternatives include sulfapyridine or sulfasalazine.\n\n4.  **Ethical and Comprehensive Care Principles:**\n    *   **Shared Decision-Making:** The patient's autonomy must be respected. While the GFD is the ideal treatment, a patient's informed refusal due to valid constraints must be acknowledged. The physician's duty is to provide all relevant information about the risks of not following the GFD (persistent gut inflammation, malabsorption, increased EATL risk) and the risks/benefits of pharmacologic options.\n    *   **Holistic Management:** Managing DH is not just about the skin. The underlying celiac disease persists as long as gluten is consumed. Therefore, comprehensive care for a patient on dapsone alone must include surveillance for the extra-cutaneous complications of untreated celiac disease. This includes monitoring for malabsorption-related nutritional deficiencies (iron, folate, vitamin D, vitamin B12), assessing bone mineral density, and managing the risk of functional hyposplenism (which increases susceptibility to encapsulated organisms) by recommending appropriate vaccinations. Collaboration with a gastroenterologist is best practice.\n\n### Option-by-Option Analysis\n\n**A. Reassure the patient that lymphoma risk is negligible in dermatitis herpetiformis, start dapsone without baseline testing, schedule follow-up as needed, and forgo gastroenterology involvement since cutaneous control suffices.**\n- **Analysis:** This option is fundamentally flawed and dangerous. The risk of EATL in untreated celiac disease, while not high in absolute numbers, is significantly elevated compared to the general population or patients on a GFD; calling it \"negligible\" is a medically inaccurate false reassurance. Starting dapsone without baseline G6PD screening is a severe violation of the standard of care and risks inducing severe hemolytic anemia. Ignoring the systemic nature of the disease and forgoing gastroenterology consultation neglects critical long-term health risks.\n- **Verdict:** Incorrect.\n\n**B. Engage in shared decision-making to convey that ongoing gluten exposure perpetuates autoantigen stimulation and thus maintains mucosal autoimmunity and increases lymphoma risk relative to strict gluten avoidance; initiate dapsone for rapid cutaneous symptom control at the lowest effective dose with baseline G6PD screening, CBC, LFTs, and methemoglobin assessment plus periodic monitoring; counsel on adverse effects (hemolysis, methemoglobinemia, agranulocytosis, neuropathy) and consider sulfapyridine or sulfasalazine if dapsone is contraindicated; coordinate gastroenterology follow-up to monitor celiac serologies, nutritional status (iron, folate, vitamin D), and bone mineral density, with endoscopic evaluation only if clinically indicated; discuss vaccinations pertinent to potential hyposplenism; explicitly state that pharmacologic suppression does not reduce intestinal autoimmunity or malignancy risk, and set a plan to revisit dietary adoption when feasible.**\n- **Analysis:** This option perfectly encapsulates the principles of best practice. It balances patient autonomy with accurate risk communication (shared decision-making). It follows all requisite safety protocols for dapsone initiation and monitoring (G6PD, CBC, LFTs). It considers alternative therapies. Critically, it addresses the comprehensive, systemic nature of the disease by planning for surveillance of nutritional status, bone health, and infectious risk (hyposplenism), and involves gastroenterology appropriately. It clearly separates the symptomatic benefit of dapsone from the lack of effect on the underlying disease process and long-term risks. Finally, it maintains a therapeutic alliance by planning to revisit the GFD.\n- **Verdict:** Correct.\n\n**C. Start long-term systemic corticosteroids to suppress skin inflammation and allow normal diet, emphasizing that steroid immunosuppression will offset lymphoma risk, and defer laboratory monitoring to reduce burden.**\n- **Analysis:** This management plan is inappropriate. Systemic corticosteroids are not the standard of care for long-term management of DH due to their extensive side-effect profile (Cushingoid features, osteoporosis, diabetes, etc.) and inferior efficacy compared to dapsone for neutrophilic dermatoses. The assertion that steroid immunosuppression offsets lymphoma risk is not evidence-based and is biologically questionable. Deferring laboratory monitoring for a patient on long-term steroids is negligent.\n- **Verdict:** Incorrect.\n\n**D. Initiate an anti–tumor necrosis factor biologic for cutaneous control, discontinue discussion of gluten-free diet, and rely on the biologic to prevent enteropathy-associated complications, with no need for G6PD, CBC, or LFT assessment.**\n- **Analysis:** This option is incorrect on multiple fronts. Anti-TNF agents are not indicated or effective for DH, which is an IgA- and neutrophil-driven process, not a primarily TNF-α-mediated one. There is no evidence that these biologics would prevent EATL or other celiac complications. Discontinuing the discussion of the GFD is poor medical practice. Finally, all biologic therapies require extensive baseline and ongoing safety monitoring, so the claim of \"no need for... assessment\" is false.\n- **Verdict:** Incorrect.\n\n**E. Insist on strict gluten elimination as the sole therapy and withhold pharmacologic agents, accepting persistent pruritus until the patient changes their mind about diet, since symptom control is secondary to immunologic cure.**\n- **Analysis:** This approach is ethically unacceptable. It is overly paternalistic, disregarding the patient's stated constraints and autonomy. While a GFD is the definitive treatment, withholding effective symptomatic relief for an intensely pruritic and distressing condition amounts to causing unnecessary suffering. The physician's duty includes alleviating symptoms and improving quality of life, especially when a safe and effective agent like dapsone is available.\n- **Verdict:** Incorrect.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once a decision is made to initiate pharmacotherapy, ensuring patient safety is the highest priority. This exercise  focuses on the most critical safety check associated with dapsone: the heightened risk of drug-induced hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. By calculating a risk-adjusted dose, you will apply a fundamental principle of clinical pharmacology and practice the thought process for selecting safer, alternative therapies when necessary.",
            "id": "4433665",
            "problem": "A patient aged $32$ years with biopsy-proven dermatitis herpetiformis characterized by granular Immunoglobulin A (IgA) deposition in the dermal papillae and clinical response to dapsone presents with known glucose-6-phosphate dehydrogenase (G6PD) deficiency documented by quantitative enzymatic activity at $0.2$ of normal. In G6PD deficiency, oxidant stress from dapsone metabolites elevates the risk of hemolytic anemia and methemoglobinemia. To reduce this risk, you elect to cap the dapsone regimen at $0.5$ mg/kg/day regardless of clinical severity.\n\nThe patient’s body weight is $83.75$ kg. Compute the risk-adjusted daily dapsone dose under this cap. Express the final dose in mg and round your answer to three significant figures.\n\nSeparately, outline a rational alternative framework using sulfapyridine, noting how dosing could be structured if dapsone is contraindicated or limited by toxicity, without performing any additional calculations for sulfapyridine.",
            "solution": "The problem presents a clinical scenario requiring a dose calculation and a conceptual discussion of an alternative treatment. I will first validate the problem statement and then proceed to the solution.\n\n### Step 1: Extract Givens\n- Patient age: $32$ years\n- Diagnosis: Dermatitis herpetiformis, confirmed by biopsy showing granular Immunoglobulin A (IgA) deposition and clinical response to dapsone.\n- Comorbidity: Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n- G6PD enzyme activity: $0.2$ of normal.\n- Clinical constraint: The dapsone regimen is capped at $0.5$ mg/kg/day to mitigate the risk of hemolytic anemia and methemoglobinemia.\n- Patient's body weight: $83.75$ kg.\n- Task 1: Compute the risk-adjusted daily dapsone dose in mg, rounded to three significant figures.\n- Task 2: Outline a rational alternative framework using sulfapyridine.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The pathophysiology described is accurate. Dermatitis herpetiformis is an autoimmune blistering disease strongly associated with celiac disease, characterized by granular IgA deposits. Dapsone is the first-line treatment. The risk of dapsone-induced hemolysis and methemoglobinemia, and its exacerbation in G6PD-deficient individuals, is a cornerstone of clinical pharmacology. The described dose-capping strategy is a standard risk-mitigation approach.\n- **Well-Posedness**: The problem provides all necessary data for the calculation: the specific dose cap per unit of body weight and the patient's body weight. The rounding instruction is precise. The second part asks for a conceptual outline, which is a standard form of inquiry in clinical sciences. A unique and meaningful solution exists for both parts.\n- **Objectivity**: The problem is stated in clear, unbiased clinical language.\n\nThe problem does not violate any of the invalidity criteria. It is a valid, formalizable problem rooted in established medical principles.\n\n### Step 3: Verdict and Action\nThe problem is valid. I will proceed with the solution, which consists of two parts as requested.\n\n### Part 1: Dapsone Dose Calculation\n\nThe risk-adjusted daily dose is determined by applying the specified cap to the patient's body weight.\n\nLet $W$ be the patient's body weight and $D_{\\text{cap}}$ be the capped dose per kilogram per day.\nThe given values are:\n- Body weight, $W = 83.75$ kg.\n- Dose cap, $D_{\\text{cap}} = 0.5$ mg/kg/day.\n\nThe total daily dose, $D_{\\text{total}}$, is the product of the body weight and the dose cap:\n$$D_{\\text{total}} = W \\times D_{\\text{cap}}$$\nSubstituting the given values:\n$$D_{\\text{total}} = (83.75 \\, \\text{kg}) \\times (0.5 \\, \\frac{\\text{mg}}{\\text{kg} \\cdot \\text{day}})$$\n$$D_{\\text{total}} = 41.875 \\, \\frac{\\text{mg}}{\\text{day}}$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value is $41.875$. The first three significant figures are $4$, $1$, and $8$. The fourth digit is $7$, which is greater than or equal to $5$, so we round up the third digit ($8$) to $9$.\nTherefore, the rounded risk-adjusted daily dose is $41.9$ mg.\n\n### Part 2: Alternative Framework Using Sulfapyridine\n\nIf dapsone is contraindicated (e.g., due to severe G6PD deficiency) or limited by unacceptable toxicity (e.g., significant hemolysis even at a low dose), an alternative therapeutic agent is required. Sulfapyridine is a well-established second-line treatment for dermatitis herpetiformis.\n\nA rational framework for using sulfapyridine would be as follows:\n\n1.  **Rationale for Selection**: Sulfapyridine is an effective sulfonamide for controlling dermatitis herpetiformis. While generally less potent than dapsone, it does not carry the same high level of risk for oxidant-induced hemolysis and is therefore a safer option in patients with G6PD deficiency. It is considered the primary alternative when dapsone cannot be used.\n\n2.  **Dosing Structure**:\n    - **Initiation**: Treatment should begin at a low dose to assess for hypersensitivity and other immediate adverse effects. A typical starting dose is $500$ mg once or twice daily.\n    - **Titration**: The dose is gradually increased every $3$ to $7$ days based on clinical response (reduction in pruritus and new lesion formation) and patient tolerance.\n    - **Maintenance**: The dosage is titrated upwards to achieve and maintain disease control. The typical maintenance dose ranges from $1$ gram to $4$ grams per day, administered in divided doses ($2$ to $4$ times daily) to maintain stable plasma concentrations and minimize gastrointestinal side effects. The goal is to use the lowest effective dose that keeps the patient free of symptoms and new lesions.\n\n3.  **Required Monitoring**: As with other sulfonamides, sulfapyridine requires careful monitoring.\n    - **Baseline**: Before initiation, a complete blood count (CBC) with differential, renal function tests (e.g., serum creatinine), and liver function tests (e.g., ALT, AST) should be obtained.\n    - **Ongoing**: Regular monitoring of CBC is critical, especially during the first few months of therapy, to screen for potential hematologic toxicities such as agranulocytosis, aplastic anemia, or thrombocytopenia. Renal and hepatic function should also be monitored periodically. Patients should be counseled to maintain adequate hydration to prevent crystalluria.\n\nThis structured approach allows for the safe and effective use of sulfapyridine as an alternative to dapsone in managing dermatitis herpetiformis in a high-risk patient with G6PD deficiency.",
            "answer": "$$\\boxed{41.9}$$"
        },
        {
            "introduction": "While pharmacologic agents control skin manifestations, only a strict gluten-free diet addresses the underlying autoimmune process. This practice allows you to quantify the success of this definitive therapy by modeling the clearance of pathogenic autoantibodies from circulation. By applying the principles of first-order kinetics , you will gain a tangible understanding of how removing the antigenic trigger leads to a predictable and measurable decline in the serological markers of the disease.",
            "id": "4433736",
            "problem": "A patient with dermatitis herpetiformis (an autoimmune blistering disorder associated with gluten-sensitive enteropathy) has a baseline serum immunoglobulin A (IgA) anti–tissue transglutaminase 2 (TG2) titer of $100 \\ \\mathrm{U/mL}$. After initiation of a strict gluten-free diet (GFD), assume the antigen-driven production of IgA anti-TG2 becomes negligible and the decline of the circulating titer follows first-order kinetics. The effective half-life is $50$ days, defined as the time $T_{1/2}$ at which the concentration falls to one half of its value. Using the fundamental definition of first-order decay as governed by a first-order differential equation and the definition of half-life as a special time point of that decay, determine the expected IgA anti-TG2 titer after $6$ months of continuous strict GFD, taking $6$ months to be $180$ days for this calculation. Round your answer to four significant figures and express it in $\\mathrm{U/mL}$.",
            "solution": "The problem is first validated against the required criteria.\n\n### Step 1: Extract Givens\n- Initial IgA anti-TG2 titer: $C(0) = C_0 = 100 \\ \\mathrm{U/mL}$\n- Kinetic model: First-order decay\n- Post-GFD assumption: Antigen-driven production becomes negligible.\n- Effective half-life: $T_{1/2} = 50$ days\n- Time for calculation: $t = 180$ days (stated as equivalent to $6$ months)\n- Required output: Titer at $t=180$ days, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded. The decay of antibody titers following antigen removal (in this case, gluten in a patient with gluten-sensitive enteropathy) is a well-established immunological phenomenon, and modeling this process with first-order kinetics is a standard and appropriate approach in pharmacokinetics and immunology. The given half-life of $50$ days for an IgA subtype is biologically plausible. The problem is well-posed, providing a clear initial condition, a kinetic model, a defined parameter ($T_{1/2}$), and a specific time point for evaluation. It is self-contained, consistent, and uses objective, precise language. No flaws are identified.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\nThe decay of the circulating titer is stated to follow first-order kinetics. Let $C(t)$ represent the concentration (titer) of IgA anti-TG2 at time $t$. According to the definition of first-order kinetics, the rate of change of the concentration is directly proportional to the concentration itself. This is expressed by the following first-order linear ordinary differential equation:\n$$\n\\frac{dC(t)}{dt} = -k C(t)\n$$\nwhere $k$ is the positive first-order rate constant, and the negative sign indicates that the concentration is decreasing over time.\n\nThis differential equation can be solved by separation of variables:\n$$\n\\frac{dC}{C} = -k \\, dt\n$$\nIntegrating both sides from the initial time $t=0$ to a later time $t$:\n$$\n\\int_{C_0}^{C(t)} \\frac{1}{C'} \\, dC' = \\int_{0}^{t} -k \\, dt'\n$$\nwhere $C_0$ is the initial concentration at $t=0$. The integration yields:\n$$\n[\\ln(C')]_{C_0}^{C(t)} = [-kt']_{0}^{t}\n$$\n$$\n\\ln(C(t)) - \\ln(C_0) = -kt\n$$\n$$\n\\ln\\left(\\frac{C(t)}{C_0}\\right) = -kt\n$$\nExponentiating both sides gives the solution for $C(t)$:\n$$\nC(t) = C_0 \\exp(-kt)\n$$\nThe problem provides the half-life, $T_{1/2}$, which is defined as the time required for the concentration to fall to one-half of its initial value. We use this information to determine the rate constant $k$. At $t = T_{1/2}$, the concentration is $C(T_{1/2}) = \\frac{1}{2} C_0$. Substituting this into the general solution:\n$$\n\\frac{1}{2} C_0 = C_0 \\exp(-k T_{1/2})\n$$\nDividing by $C_0$ (which is non-zero):\n$$\n\\frac{1}{2} = \\exp(-k T_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k T_{1/2}\n$$\nUsing the property of logarithms $\\ln(1/x) = -\\ln(x)$:\n$$\n-\\ln(2) = -k T_{1/2}\n$$\nSolving for the rate constant $k$:\n$$\nk = \\frac{\\ln(2)}{T_{1/2}}\n$$\nNow we substitute this expression for $k$ back into the solution for $C(t)$:\n$$\nC(t) = C_0 \\exp\\left(-\\frac{\\ln(2)}{T_{1/2}} t\\right)\n$$\nThis equation can be rewritten in a more direct form using the properties of exponents:\n$$\nC(t) = C_0 \\left(\\exp(\\ln(2))\\right)^{-t/T_{1/2}} = C_0 \\cdot 2^{-t/T_{1/2}}\n$$\nWe are given the following values:\nInitial concentration, $C_0 = 100 \\ \\mathrm{U/mL}$\nHalf-life, $T_{1/2} = 50$ days\nTime, $t = 180$ days\n\nSubstituting these values into the equation for $C(t)$:\n$$\nC(180) = 100 \\cdot 2^{-180/50}\n$$\nFirst, we evaluate the exponent:\n$$\n\\frac{180}{50} = \\frac{18}{5} = 3.6\n$$\nSo, the equation becomes:\n$$\nC(180) = 100 \\cdot 2^{-3.6}\n$$\nNow we calculate the numerical value:\n$$\n2^{-3.6} \\approx 0.08246718...\n$$\n$$\nC(180) = 100 \\times 0.08246718... = 8.246718...\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $8$, $2$, $4$, and $6$. The fifth digit is $7$, which is $5$ or greater, so we round up the fourth significant digit.\n$$\nC(180) \\approx 8.247 \\ \\mathrm{U/mL}\n$$\nThus, the expected IgA anti-TG2 titer after $6$ months ($180$ days) is $8.247 \\ \\mathrm{U/mL}$.",
            "answer": "$$\\boxed{8.247}$$"
        }
    ]
}